
Releases
ADMA Biologics Faces Class Action Over Alleged Revenue Manipulation
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, are being urged to join a class action lawsuit filed against the company. The litigation, initiated by Bronstein, Gewirtz & Grossman, LLC, claims the biopharmaceutical firm misled shareholders regarding its internal financial health and revenue practices.























